MNG25
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.310
- PANCREAS_BETA_CELLS+0.307
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.252
- COAGULATION+0.242
- INTERFERON_ALPHA_RESPONSE+0.218
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.206
- PEROXISOME+0.187
- FATTY_ACID_METABOLISM+0.154
- KRAS_SIGNALING_DN+0.144
- NOTCH_SIGNALING+0.120
Top 10 suppressed
- G2M_CHECKPOINT-0.480
- E2F_TARGETS-0.434
- MITOTIC_SPINDLE-0.430
- MYC_TARGETS_V2-0.388
- PROTEIN_SECRETION-0.360
- ANDROGEN_RESPONSE-0.335
- UNFOLDED_PROTEIN_RESPONSE-0.306
- IL6_JAK_STAT3_SIGNALING-0.274
- PI3K_AKT_MTOR_SIGNALING-0.264
- MYC_TARGETS_V1-0.254
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-GM-A2D9-01A-11R-A18M-07 | — | B | 0.854 |
| 2 | SRR1403222 | GTEX | — | 0.846 |
| 3 | BS_0BXY0F9N | Posterior Fossa Ependymoma | — | 0.804 |
| 4 | SRR1458044 | GTEX | — | 0.773 |
| 5 | TCGA-AO-A126-01A-11R-A10J-07 | — | A | 0.772 |
| 6 | TCGA-GM-A5PX-01A-12R-A28M-07 | — | A | 0.772 |
| 7 | SRR975560 | — | — | 0.769 |
| 8 | 60c210ff-d245-40d2-9de9-7b799cc3ffc9 | — | — | 0.768 |
| 9 | SRR1329761 | GTEX | — | 0.761 |
| 10 | TCGA-C8-A12N-01A-11R-A115-07 | — | A | 0.752 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.310 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.307 | Cobimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.252 | Inavolisib | — uncovered |
| COAGULATION | 0.242 | Binimetinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.218 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.206 | Inavolisib | — uncovered |
| PEROXISOME | 0.187 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.154 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.144 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.120 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.117 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.073 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.065 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.061 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.058 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.058 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.058 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.035 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.032 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.032 | Idelalisib | — uncovered |